These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 15642075)

  • 1. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
    Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
    Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.